Discontinued — last reported Q2 '23

Business Segments · Accumulated goodwill impairment loss

Pharmaceutical — Accumulated goodwill impairment loss

Cardinal Health Pharmaceutical — Accumulated goodwill impairment loss remained flat by 0.0% to $829.00M in Q2 2023 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $829.00M to $829.00M. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ2 2017
Last reportedQ2 2023

How to read this metric

An increase signals that past acquisitions have failed to meet performance expectations, potentially indicating poor capital allocation.

Detailed definition

The cumulative total of impairment charges recognized against goodwill within the segment over time. This reflects histo...

Peer comparison

Investors monitor this to assess the long-term success and valuation accuracy of a company's M&A strategy.

Metric ID: cah_segment_pharmaceutical_accumulated_goodwill_impairment_loss

Historical Data

5 periods
 Q2 '21Q4 '21Q1 '22Q2 '22Q2 '23
Value$829.00M$829.00M$829.00M$829.00M$829.00M
QoQ Change+0.0%+0.0%+0.0%+0.0%
YoY Change+0.0%+0.0%
Range$829.00M$829.00M
CAGR+0.0%
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Cardinal Health's pharmaceutical — accumulated goodwill impairment loss?
Cardinal Health (CAH) reported pharmaceutical — accumulated goodwill impairment loss of $829.00M in Q2 2023.
How has Cardinal Health's pharmaceutical — accumulated goodwill impairment loss changed year-over-year?
Cardinal Health's pharmaceutical — accumulated goodwill impairment loss decreased by 0.0% year-over-year, from $829.00M to $829.00M.
What does pharmaceutical — accumulated goodwill impairment loss mean?
The total historical value lost from goodwill write-downs within this segment.